This receptor dissociation guided the development of OX2R-selective agonists, such as danavorexton and oveporexton [59,60], which restore wakefulness and suppress cataplexy by targeting the principal pathway mediating sleep stability. This evidence concerns the gene HCRTR2 and Cataplexy.